×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SGMT – sagimet biosciences inc. - series a (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SGMT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/3
08:03 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
2/3
08:00 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
2/2
07:00 am
sgmt
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
High
Report
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
1/30
08:41 am
sgmt
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal [Seeking Alpha]
High
Report
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal [Seeking Alpha]
1/29
07:41 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at Barclays PLC to a "hold" rating.
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at Barclays PLC to a "hold" rating.
1/29
06:00 am
sgmt
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
High
Report
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
1/29
06:00 am
sgmt
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
High
Report
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
1/27
07:02 pm
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was given a new $8.00 price target on by analysts at Barclays PLC.
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) was given a new $8.00 price target on by analysts at Barclays PLC.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/2
07:06 am
sgmt
Form 8-K Sagimet Biosciences Inc. For: Feb 02
High
Report
Form 8-K Sagimet Biosciences Inc. For: Feb 02
12/18
04:50 pm
sgmt
Form SCHEDULE 13G/A Sagimet Biosciences Inc. Filed by: KPCB PANDEMIC & BIO DEFENSE FUND LLC
Medium
Report
Form SCHEDULE 13G/A Sagimet Biosciences Inc. Filed by: KPCB PANDEMIC & BIO DEFENSE FUND LLC
12/18
07:06 am
sgmt
Form 8-K Sagimet Biosciences Inc. For: Dec 18
Medium
Report
Form 8-K Sagimet Biosciences Inc. For: Dec 18
12/17
07:06 am
sgmt
Form 8-K Sagimet Biosciences Inc. For: Dec 17
Low
Report
Form 8-K Sagimet Biosciences Inc. For: Dec 17
11/21
06:13 pm
sgmt
Form 4 Sagimet Biosciences Inc. For: Nov 20 Filed by: Kemble George
Low
Report
Form 4 Sagimet Biosciences Inc. For: Nov 20 Filed by: Kemble George
11/20
04:22 pm
sgmt
Form 144 Sagimet Biosciences Inc. Filed by: Kemble George
Medium
Report
Form 144 Sagimet Biosciences Inc. Filed by: Kemble George
11/14
04:21 pm
sgmt
Form SCHEDULE 13G/A Sagimet Biosciences Inc. Filed by: Woodline Partners LP
Low
Report
Form SCHEDULE 13G/A Sagimet Biosciences Inc. Filed by: Woodline Partners LP
11/13
07:36 am
sgmt
Form 8-K Sagimet Biosciences Inc. For: Nov 13
High
Report
Form 8-K Sagimet Biosciences Inc. For: Nov 13
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: